208 related articles for article (PubMed ID: 35681470)
21. Effects of Small Molecule Ligands on ACKR3 Receptors.
Hopkins BE; Masuho I; Ren D; Iyamu ID; Lv W; Malik N; Martemyanov KA; Schiltz GE; Miller RJ
Mol Pharmacol; 2022 Sep; 102(3):128-138. PubMed ID: 35809897
[TBL] [Abstract][Full Text] [Related]
22. Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function.
Cheng YH; Eby JM; LaPorte HM; Volkman BF; Majetschak M
PLoS One; 2017; 12(11):e0187949. PubMed ID: 29125867
[TBL] [Abstract][Full Text] [Related]
23. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma.
Rusetska N; Kowalski K; Zalewski K; Zięba S; Bidziński M; Goryca K; Kotowicz B; Fuksiewicz M; Kopczynski J; Bakuła-Zalewska E; Kowalik A; Kowalewska M
J Clin Pathol; 2022 May; 75(5):324-332. PubMed ID: 33692092
[TBL] [Abstract][Full Text] [Related]
24. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.
Décaillot FM; Kazmi MA; Lin Y; Ray-Saha S; Sakmar TP; Sachdev P
J Biol Chem; 2011 Sep; 286(37):32188-97. PubMed ID: 21730065
[TBL] [Abstract][Full Text] [Related]
25. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
[TBL] [Abstract][Full Text] [Related]
26. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
27. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways.
Drury LJ; Ziarek JJ; Gravel S; Veldkamp CT; Takekoshi T; Hwang ST; Heveker N; Volkman BF; Dwinell MB
Proc Natl Acad Sci U S A; 2011 Oct; 108(43):17655-60. PubMed ID: 21990345
[TBL] [Abstract][Full Text] [Related]
28. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
29. Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.
Murphy PM; Heusinkveld L
Cytokine; 2018 Sep; 109():2-10. PubMed ID: 29398278
[TBL] [Abstract][Full Text] [Related]
30. ACKR3 promotes CXCL12/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production.
Antonello P; Pizzagalli DU; Foglierini M; Melgrati S; Radice E; Thelen S; Thelen M
Front Immunol; 2022; 13():1067885. PubMed ID: 36713377
[TBL] [Abstract][Full Text] [Related]
31. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
32. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
[TBL] [Abstract][Full Text] [Related]
33. Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.
Szpakowska M; Dupuis N; Baragli A; Counson M; Hanson J; Piette J; Chevigné A
Biochem Pharmacol; 2016 Aug; 114():14-21. PubMed ID: 27238288
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
35. Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases.
Duval V; Alayrac P; Silvestre JS; Levoye A
Front Endocrinol (Lausanne); 2022; 13():906586. PubMed ID: 35846294
[TBL] [Abstract][Full Text] [Related]
36. α
Albee LJ; Eby JM; Tripathi A; LaPorte HM; Gao X; Volkman BF; Gaponenko V; Majetschak M
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862946
[TBL] [Abstract][Full Text] [Related]
37. The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker.
Yan Y; Su J; Zhang Z
Cell Mol Neurobiol; 2022 Oct; 42(7):2147-2156. PubMed ID: 34117967
[TBL] [Abstract][Full Text] [Related]
38. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
Yen YC; Schafer CT; Gustavsson M; Eberle SA; Dominik PK; Deneka D; Zhang P; Schall TJ; Kossiakoff AA; Tesmer JJG; Handel TM
Sci Adv; 2022 Jul; 8(28):eabn8063. PubMed ID: 35857509
[TBL] [Abstract][Full Text] [Related]
39. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.
Uto-Konomi A; McKibben B; Wirtz J; Sato Y; Takano A; Nanki T; Suzuki S
Biochem Biophys Res Commun; 2013 Feb; 431(4):772-6. PubMed ID: 23333329
[TBL] [Abstract][Full Text] [Related]
40. Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function.
Bach HH; Wong YM; Tripathi A; Nevins AM; Gamelli RL; Volkman BF; Byron KL; Majetschak M
Mol Med; 2014 Oct; 20(1):435-47. PubMed ID: 25032954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
